News and Events
2018
Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China
May 30, 2018
Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China
SAN JOSE, Calif.,May 30, 2018--Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and distribute TPU’s flagship product, Lidoderm®, in China. Lidoderm® offers relief of the pain associated with post-herpetic neuralgia (“PHN”). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.
2017
Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
August 22, 2017
Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
SAN JOSE, Calif., Aug. 22, 2017—Teikoku Pharma USA, Inc. (Teikoku Pharma) today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 3-day dexmedetomidine transdermal patch, a novel drug delivery system with a non-opioid active moiety for the management of post-surgical pain. The preliminary results demonstrate that the patch provides effective pain control across several parameters and produced no unexpected safety events in a postoperative setting.
2016
Teikoku Pharma USA and Luoxin Pharmaceutical Enter into License Agreement for Docetaxel, Non-Alcohol Formula
September 6, 2016
SAN JOSE, Calif., September 6, 2016 -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell and distribute TPU's Docetaxel Injection, Non-Alcohol Formula in China.
READ MOREEagle Pharmaceuticals Announces Commercial Availability of Docetaxel Injection, Non-Alcohol Formula
February 2, 2016
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
2015
Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula
December 28, 2015
San Jose, Calif., Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
READ MORE